已收盘 12-19 16:00:00 美东时间
-0.070
-2.46%
Rithm Property Trust (RPT) announced board approval of a one-for-six reverse stock split of its common stock. The reverse stock split is expected to take effect on December 30, 2025. Outstanding commo...
12-20 05:40
Rithm Property Trust Inc. (NYSE:RPT, "RPT" or the "Company"))) today announced that its Board of Directors unanimously approved a one-for-six reverse stock split (the "Reverse Stock Split") of the Company's issued and outstanding shares of common stock (the "Common Stock").
12-20 05:32
<span style="color:#999999;">编者按:聚焦公司高管观点与展望,深挖业绩背后的信息,助力投资者把握先机。</span><blockquote><p><span style="color:#fa1432;"><strong>业绩回顾</strong></span></p></blockquote><p>• 根据Rithm Property Trust业绩会实录,以下是财务业绩回顾摘要: ## 1. 财务业绩:**盈利状况**:公司本季度业绩基本持平,CEO表示"公司本质上是持平的,当你考虑到收益时"。公司已从此前每季度亏损约1000万美元的状态稳定至盈亏平衡。 **股息支付**:维持每股0.06美元的季度股息,与上季度保持一致。 **现金状况**:季度末现金及现金等价物约8100万美元,总流动资金约1亿美元。 **资产规模**:投资组合总规模约3.08亿美元,总股东权益2.92亿美元。 **新增业务**:本季度新增放贷2100万美元,为西雅图郊外一个以
11-03 12:11
Companies Reporting Before The Bell • T. Rowe Price Group (NASDAQ:TROW) is esti...
10-31 19:11
Rithm Property Trust (NYSE:RPT) reported quarterly losses of $(0.02) per share which missed the analyst consensus estimate of $0.04 by 150 percent. The company reported quarterly sales of $3.988 million which missed the
10-31 18:48
Earnings Call Insights: DaVita Inc. (DVA) Q3 2025 Management View CEO Javier Rodriguez highlighted that "our third quarter performance was in line with our expectations and keeps us on track to achiev...
10-30 07:47
Rapid7 announced new AI-generated risk intelligence and vulnerability intelligence capabilities within its Rapid7 Command Platform, aimed at helping security teams prioritize, collaborate, and remediate faster. These features, delivered through Remediation Hub and Intelligence Hub, transform vulnerability data into actionable risk insights, enabling teams to reduce exposure and improve response times. The updates include AI-generated risk summari...
10-29 13:00
RAPT Therapeutics has initiated a Phase 2b trial for ozureprubart to treat IgE-mediated food allergies, building on promising Phase 2 results in chronic spontaneous urticaria. The trial, called prestIgE, will evaluate the efficacy and safety of ozureprubart in approximately 100 participants across the U.S., Canada, and Australia. Ozureprubart, a half-life extended anti-IgE monoclonal antibody, is designed to offer improved durability and reduced ...
10-27 12:00
Rapt Therapeutics Inc (($RAPT)) announced an update on their ongoing clinical s...
10-25 00:30